期刊文献+

奥氮平与艾司西酞普兰联用治疗抑郁症患者的疗效及对血清BDNF、S100B蛋白和炎性因子指标的影响 被引量:6

下载PDF
导出
摘要 目的:探讨奥氮平与艾司西酞普兰联用治疗抑郁症患者的疗效及对血清BDNF、S100B蛋白和炎性因子指标的影响。方法:选取2015年6月—2016年10月间收治的抑郁症患者80例,采用随机分组法将其分为观察组(n=40)和对照组(n=40);对照组患者给予草酸艾司西酞普兰治疗,观察组患者在对照组基础上加用奥氮平治疗,比较两组患者治疗后的总有效率和治疗前后血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、脑源性神经营养因子(BDNF)、神经功能相关因子(S100B)蛋白测得值的变化情况。结果:观察组患者治疗后的总有效率为97.50%高于对照组为77.50%(P<0.05);以及两组患者治疗后血清IL-8、TNF-α、BDNF、S100B测得值优于治疗前,观察组患者治疗后血清IL-8、TNF-α、S100B测得值低于对照组,而BDNF测得值高于对照组(P<0.05)。结论:采用草酸艾司西酞普兰与奥氮平联用治疗有助于改善抑郁症患者神经功能,降低血清IL-8、TNF-α、S100B指标,提高了血清BDNF指标。
出处 《抗感染药学》 2017年第3期624-626,共3页 Anti-infection Pharmacy
  • 相关文献

参考文献6

二级参考文献88

  • 1MONTGOMERY SA.Clinically relevant effect sizes in depression [J].Eur Neuropsychopharcol,1994,4(4):283-284.
  • 2Anon.Practice guideline for the treatment of patients with major depressive disorder(revision).American Psychiatric Association [J].Am J Psychiatry,2000,157(4 Suppl):1-45.
  • 3SORBERA LA,MARTIN L,REVEL L,et al.Escitalopram oxalate[J].Drugs Fut,2001,26(2):115-120.
  • 4SANCHEZ C,KREILGAARD M.R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram[J].Pharm Biochem Behav,2004,77(2):391-398.
  • 5OWENS MJ,KNIGHT DL,NEMEROFF CB.Second-generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine[J].Biol Psychiatry,2001,50(5):345-350.
  • 6von MOLTKE LL,GREENBLATT DJ,GIANCARLO GM,et al. Escitalopram(Scitalopram) and its metabolites in vitro:cytochromes mediating biotransformation,inhibitory effects,and comparison to R-citalopram[J].Drug Metab Dispos,2001,29 (9):1102-1109.
  • 7YEVTUSHENKO VY,BELOUS AI,YEVTUSHENKO YG, et al.Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder:A 6-week,multicenter,prospective, randomized,double-blind,activecontrolled study in adult outpatients[J].Clin Ther 2007,29(11):2319-2332.
  • 8MOORE N,VERDOUX H,FANTINO B.Prospective,multicentre, randomized,double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder[J].Int Clin Psychopharmacol,2005,20(3): 131-137.
  • 9COLONNA L,ANDERSEN HF,REINES EH.A randomized, double blind,24-week study of escitalopram(10 mg/day) versus citalopram(20 mg/day) in primary care patients with major depressive disorder[J].Curr Med Res Opin,2005,21(10): 1659-1668.
  • 10OU JJ,XUN GL,WU RR,et al.Efficacy and safety of escitalopram versus citalopram:in major depressive disorder;a 6-week, multicenter,randomized,double-blind,flexible-dose study [J].Psychopharmacology(Berl),2011,213(2-3):639-646.

共引文献88

同被引文献50

引证文献6

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部